Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.
It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis.
It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand.
The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates.
The company was founded in 1998 and is based in Florham Park, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 2, 24 | -0.50 Decreased by -108.33% | -0.03 Decreased by -1.57 K% |
| Dec 5, 23 | -0.50 Decreased by -1.76 K% | -0.03 Decreased by -1.56 K% |
| Aug 14, 23 | -0.27 Decreased by -184.38% | -0.03 Decreased by -800.00% |
| May 22, 23 | -0.41 Increased by +14.58% | -0.24 Decreased by -70.83% |
| Mar 31, 23 | -0.24 Decreased by -700.00% | -0.25 Increased by +4.00% |
| Nov 10, 22 | 0.03 Decreased by -92.50% | -0.26 Increased by +111.54% |
| Aug 9, 22 | 0.32 Increased by +111.90% | -0.26 Increased by +223.08% |
| May 16, 22 | -0.48 Decreased by -119.35% | -0.26 Decreased by -84.62% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 3.79 M Decreased by -8.31% | -93.88 M Decreased by -484.20% | Decreased by -2.48 K% Decreased by -519.01% |
| Sep 30, 23 | 3.79 M Decreased by -8.44% | -93.88 M Decreased by -2.06 K% | Decreased by -2.48 K% Decreased by -2.24 K% |
| Jun 30, 23 | 2.94 M Decreased by -22.19% | -47.95 M Decreased by -200.26% | Decreased by -1.63 K% Decreased by -228.85% |
| Mar 31, 23 | 3.94 M Decreased by -33.70% | -64.02 M Decreased by -1.83% | Decreased by -1.63 K% Decreased by -53.58% |
| Dec 31, 22 | 4.13 M Decreased by -14.99% | 24.43 M Increased by +704.95% | Increased by +591.77% Increased by +811.61% |
| Sep 30, 22 | 4.13 M Decreased by -61.07% | 4.80 M Decreased by -90.39% | Increased by +116.06% Decreased by -75.31% |
| Jun 30, 22 | 3.78 M Increased by +18.11% | 47.83 M Increased by +174.18% | Increased by +1.27 K% Increased by +162.80% |
| Mar 31, 22 | 5.93 M Increased by +123.12% | -62.87 M Increased by +22.90% | Decreased by -1.06 K% Increased by +65.44% |